Efficacy and Safety of Cilostazol in Patients of Vascular Cognitive Impairment-no Dementia (VCIND)
NCT ID: NCT01872858
Last Updated: 2013-06-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
200 participants
INTERVENTIONAL
2010-11-30
2015-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Trial of Cilostazol in Patients With Mild Cognitive Impairment (COMCID)
NCT02491268
Treatment of Mild Vascular Cognitive Impairment With Yangxue Qingnao Pill
NCT04958512
Efficacy and Safety of TMBCZG in Mild to Moderate Vascular Dementia
NCT03230071
The Efficacy of Butylphthalide Soft Capsules in Patents With VCIND
NCT02993367
Clinical Efficacy of Ginkgo Biloba Extract in the Treatment of Alzheimer's Disease
NCT03090516
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Aspirin
Aspirin, 100mg, Q.D, p.o, 2yr
Aspirin
Aspirin, 100mg, Q.D, p.o, 2yr
Cilostazol
cilostazol, 100mg, B.I.D, p.o, 2yr
Cilostazol
cilostazol, 100mg, B.I.D, p.o, 2yr
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aspirin
Aspirin, 100mg, Q.D, p.o, 2yr
Cilostazol
cilostazol, 100mg, B.I.D, p.o, 2yr
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Small vessel disease and associated cognitive impairment, diagnosed as VCIND；
3. Non-specific subjective symptoms (dizziness, somnolence, numbness in limbs) are acceptable.
4. Normal hepatic and renal function.
5. With good compliance.
Exclusion Criteria
2. Dementia.
3. Cerebral infarction(\>2cm).
4. Major vascular lesion. (stenosis\>50%).
5. Cardiac cerebral infarction.
6. Intracerebral Hemorrhage.
7. Clinical manifestations cannot attribute to small vessel disease.
8. Major depression or dysfunction in speech, visual ability, hearing or aphasia that would interfere with the cognitive assessment.
9. Severe systematic organic impairment(cardiac, hepatic, renal dysfunction).
10. Thrombocytopenic Purpura.
11. History of hemorrhage in digestive system or surgery in past 3 months.
12. Previously on cilostazol treatment for more than 3 month.
13. Allergic to aspirin or cilostazol.
14. Enrolled in other clinical trials in past 3 months.
15. Lack of informed consent or compliance.
16. Contraindications for MRI scan.
50 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Huashan Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jianhui Fu
Department of Neurology, Huashan Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dept. of Neurology, Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
jianhuifu2013
Identifier Type: -
Identifier Source: org_study_id
NCT01862575
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.